These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38730460)

  • 1. Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus.
    Wang S; Ning W; Tang H; Mu C; Huang X
    Arthritis Res Ther; 2024 May; 26(1):98. PubMed ID: 38730460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
    Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA
    Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials.
    Panda AK; Ranjan S; Sahu JK
    Int J Rheum Dis; 2024 Jan; 27(1):e14964. PubMed ID: 37950554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
    Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
    Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
    Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab for systemic lupus erythematosus.
    Singh JA; Shah NP; Mudano AS
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L; Guo L; Wang L; Jiang X
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
    Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
    Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
    South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis.
    Haikun W; Na W; Dan S
    Medicine (Baltimore); 2022 Sep; 101(38):e30676. PubMed ID: 36197174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.